DAVENPORT & Co LLC Sells 2,388 Shares of HCA Healthcare, Inc. $HCA

DAVENPORT & Co LLC lessened its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 20.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,543 shares of the company’s stock after selling 2,388 shares during the period. DAVENPORT & Co LLC’s holdings in HCA Healthcare were worth $4,067,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Saudi Central Bank acquired a new position in HCA Healthcare during the 1st quarter worth approximately $26,000. WPG Advisers LLC acquired a new position in HCA Healthcare during the first quarter worth $27,000. Ameriflex Group Inc. bought a new stake in HCA Healthcare during the 2nd quarter worth about $27,000. Chung Wu Investment Group LLC bought a new position in shares of HCA Healthcare in the 2nd quarter valued at about $27,000. Finally, Clearstead Trust LLC raised its holdings in HCA Healthcare by 311.8% during the second quarter. Clearstead Trust LLC now owns 70 shares of the company’s stock worth $27,000 after acquiring an additional 53 shares in the last quarter. Institutional investors and hedge funds own 62.73% of the company’s stock.

HCA Healthcare Stock Up 0.7%

Shares of NYSE:HCA opened at $477.30 on Friday. The stock has a market cap of $108.92 billion, a PE ratio of 18.45, a P/E/G ratio of 1.40 and a beta of 1.36. HCA Healthcare, Inc. has a 12-month low of $289.98 and a 12-month high of $520.00. The business has a 50 day moving average of $475.66 and a 200-day moving average of $420.04.

HCA Healthcare (NYSE:HCA) last released its quarterly earnings results on Friday, October 24th. The company reported $6.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.64 by $1.32. The business had revenue of $19.16 billion during the quarter, compared to the consensus estimate of $18.55 billion. HCA Healthcare had a negative return on equity of 792.25% and a net margin of 8.53%.The firm’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the company posted $4.90 EPS. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. Equities research analysts expect that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 29th. Shareholders of record on Monday, December 15th will be issued a $0.72 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $2.88 dividend on an annualized basis and a yield of 0.6%. HCA Healthcare’s payout ratio is currently 11.13%.

Insider Activity at HCA Healthcare

In other news, EVP Michael R. Mcalevey sold 3,892 shares of HCA Healthcare stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $473.79, for a total value of $1,843,990.68. Following the completion of the sale, the executive vice president directly owned 3,487 shares in the company, valued at approximately $1,652,105.73. The trade was a 52.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on HCA shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of HCA Healthcare in a research report on Monday, October 27th. Wells Fargo & Company upped their price target on shares of HCA Healthcare from $412.00 to $431.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 13th. Raymond James Financial set a $525.00 price objective on shares of HCA Healthcare in a research note on Monday, October 27th. Robert W. Baird lifted their price target on HCA Healthcare from $423.00 to $450.00 and gave the stock a “neutral” rating in a report on Thursday, December 11th. Finally, Cowen reaffirmed a “buy” rating on shares of HCA Healthcare in a research report on Monday, October 27th. Fourteen equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $479.00.

HCA Healthcare Company Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.